Swiss stocks - Factors to watch on September 13

Fundamenta Real Estate AG

13/09/2019 06:25

ZURICH/BERLIN, Sept 13 (Reuters) - Here are some of the main
factors that may affect Swiss stocks on Friday:
    
    MONETARY POLICY 
    Further easing by the European Central Bank on Thursday adds
pressure on the Swiss National Bank to relax its already
ultra-expansive policy based on a negative interest rate of
-0.75% and currency market interventions to reduce upward
pressure on the safe-haven Swiss franc. On Thursday the SNB
declined to comment on the possible implications for its own
monetary policy after the ECB decided to lower its deposit rate
and restart its bond buying programme.  urn:newsml:reuters.com:*:nZ8N23J00F
    
    ALPIQ  ALPH.S 
    A consortium led by CSA Energie-Infrastruktur Schweiz (CSA)
has got 89.22% of shares in Swiss utility Alpiq after a 70 Swiss
francs ($70.73) per share tender offer, according to definitive
preliminary results issued on Friday.  urn:newsml:reuters.com:*:nZ8N217009
    
    NESTLE  NESN.S  
    Nestle has set up a research institute to develop more
environmentally friendly packaging for its products and reduce
plastic waste, taking matters into its own hands rather than
relying on its suppliers.  urn:newsml:reuters.com:*:nL5N2632MP
      
    COMPANY STATEMENTS  E-CH 
    * BFW Liegenschaften  BLIN.S  H1 EBIT down at CHF 9.1
million.  urn:newsml:reuters.com:*:nFWN2630IS
    * Fundamenta Real Estate AG  FREN.S  H1 net result up 54.2%
at CHF 10.09 million.  urn:newsml:reuters.com:*:nFWN2630IT 
    * Zug Estates  ZUGN.S  sees one-off positive impact of CHF
19 million in 2019.  urn:newsml:reuters.com:*:nFWN2630P9
    * Cham Group  CHAMA.S  completes share buyback program at
fixed price.  urn:newsml:reuters.com:*:nFWN2630IW
    * Roche Holding  ROG.S  said post-hoc analysis from a phase
III open-label extension study showed a 42% reduction in risk of
primary progressive MS (PPMS) patients needing a wheelchair
after 6.5 years of Ocrevus treatment compared with patients who
started Ocrevus after double-blind period.  urn:newsml:reuters.com:*:nFWN2630VE
    * Roche said Genentech's fixed dose subcutaneous combination
of perjeta and herceptin showed non-inferiority when compared to
intravenous formulations for people with HER2-positive breast
cancer.  urn:newsml:reuters.com:*:nFWN2630SS
    * Novartis  NOVN.S  said data show neuronal and glial
filaments, biomarkers of disease activity, have the potential to
support decision making in the management of multiple sclerosis
(MS) patients.  urn:newsml:reuters.com:*:nFWN2620M7
    
    ECONOMY  M-CH 
    No economic data scheduled.


($1 = 0.9897 Swiss francs)

 (Reporting by Zurich newsroom and Berlin Speed Desk)
 ((+41 58 306 7336; zurich.newsroom@thomsonreuters.com))
 
((For Top News in a multimedia Web format on Eikon visit: https://bit.ly/2NDFd6g
 FOR RELATED PRICES, NEWS AND OTHER TOPICS, DOUBLE-CLICK ON:
    
 Daily Swiss stock market report in German................ .SDE 
 All SMI constituent stocks............................ 0#.SSMI  
 News on major Swiss stock price moves.................. CH-HOT 
 FTSE Eurotop 300 index................................  .FTEU3 
 DJ STOXX index........................................  .STOXX 
 Top 10 STOXX sectors.............................  .PGL.STOXXS  
 Top 10 EUROSTOXX sectors........................  .PGL.STOXXES 
 Top 10 Eurotop 300 sectors.......................  .PGL.FTEU3S 
 Top 25 European pct gainers...  .PG.PEUR , losers...  .PL.PEUR 
    
 Swiss mid-cap index      .SSMI   SMI futures            0#SMI: 
 Swiss all-share index    .SSHI   Market statistics   CH/STATS1 
 Swiss market digest      .AD.S   Sector overview    CH/SECTOR1 
 All Swiss news              CH   Swiss research news     CH-RCH   
 All equity news              E  
     
 INTERNET ADDRESSES:              
 
Swiss Exchange  www.swx.ch/     
STOXX Ltd         www.stoxx.com 
 
 SPEED GUIDES:   EQUITY   EQUITY/NEWS1   EUR/EQUITY  
  SWITZERLAND   REUTERS  ))